Opinion|Videos|July 11, 2024
Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives
The panel examines the current positioning of CAR T-cell therapy within the treatment paradigm for Relapsed / Refractory Acute Lymphoblastic Leukemia, considering the distinctions between Philadelphia chromosome-positive and negative patients.
Advertisement
Video content above is prompted by the following:
- Where does CAR T-cell therapy currently fall in your treatment paradigm?
- Does it differ between patients who are Philadelphia positive vs. negative, or those with high-risk features, or extramedullary disease?
- How does bulk of disease or percentage of blasts factor into your decision making?
Advertisement
Related to this article
Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.
Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.
The FDA has granted fast track designation to varsetatug masetecan for relapsed/refractory metastatic colorectal cancer.
SYS6090, a first-in-class PD-1/IL-15 bispecific fusion protein, earned fast track status for MSS/pMMR metastatic colorectal cancer that has progressed on standard systemic therapy.
Cathy Eng, MD, FACP, FASCO, discusses how oncology fellows can navigate the journal submission and review process.
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
4
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
5